Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4413629 | 0.69 | ESR1 (0.45) | — | |
| SCHEMBL743279 | 0.69 | — | — | |
| SCHEMBL3217781 | 0.67 | — | — | |
| SCHEMBL887697 | 0.67 | APLNR (0.33) | APLNR | |
| SCHEMBL22309015 | 0.67 | — | — | |
| SCHEMBL1765140 | 0.67 | SLC22A1 (0.31) | — | |
| SCHEMBL19865080 | 0.67 | SLC22A1 (0.31) | — | |
| SCHEMBL1837870 | 0.65 | APLNR (0.50) | APLNR | |
| SCHEMBL849927 | 0.65 | APLNR (0.80) | APLNR | |
| SCHEMBL11602436 | 0.65 | ALDH1A1 (0.38) | APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2238131-A1 | 5-O-SUBSTITUTED 3-N-PHENYL-1,3,4-OXADIAZOLONES FOR MEDICAL USE | BIAL - Portela & Ca., S.A. (PT) | 2010-10-13 | — | — | EP | claimed |
| WO-2009084970-A1 | 5-O-SUBSTITUTED 3-N-PHENYL-1,3,4-OXADIAZOLONES FOR MEDICAL USE | BIAL-PORTELA & COMPANHIA, S.A. (PT) | 2009-07-09 | — | — | WO | claimed |
| EP-1482929-A1 | USE OF SUBSTITUTED 3-PHENYL-5-ALKOXY-1,3,4-OXDIAZOLE-2-ONE FOR PRODUCING MEDICAMENTS THAT INHIBIT PANCREATIC LIPASE | Aventis Pharma Deutschland GmbH (DE) | 2004-12-08 | — | — | EP | claimed |
| US-20030236288-A1 | Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase | AVENTIS PHARMA DEUTSCHLAND GMBH | 2003-12-25 | — | — | US | claimed |
| EP-1214302-B1 | SUBSTITUTED 3-PHENYL-5-ALKOXI-1,3,4-OXDIAZOL-2-ONES AND THEIR USE AS LIPASE INHIBITORS | AVENTIS PHARMA GMBH (DE) | 2003-10-29 | — | — | EP | claimed |
| WO-2003072098-A1 | USE OF SUBSTITUTED 3-PHENYL-5-ALKOXY-1,3,4-OXDIAZOLE-2-ONE FOR PRODUCING MEDICAMENTS THAT INHIBIT PANCREATIC LIPASE | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-09-04 | — | — | WO | claimed |
| US-6596742-B1 | Inhibitory effect on the hormone-sensitive lipase, HSL. insecticides, controlling metabolism and multistage synthesis | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-07-22 | — | — | US | claimed |
| EP-1214302-A1 | SUBSTITUTED 3-PHENYL-5-ALKOXI-1,3,4-OXDIAZOL-2-ONES AND THEIR USE AS LIPASE INHIBITORS | Aventis Pharma Deutschland GmbH (DE) | 2002-06-19 | — | — | EP | claimed |
| WO-2001017981-A1 | SUBSTITUTED 3-PHENYL-5-ALKOXI-1,3,4-OXDIAZOL-2-ONES AND THEIR USE AS LIPASE INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-03-15 | — | — | WO | claimed |
| US-20230190943-A1 | ALGINIC ACID DERIVATIVE BONDED TO NONSTEROIDAL ANTI-INFLAMMATORY COMPOUND | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2023-06-22 | — | — | US | disclosed |
| EP-3770180-A1 | ALGINIC ACID DERIVATIVE BONDED TO NONSTEROIDAL ANTI-INFLAMMATORY COMPOUND | Mochida Pharmaceutical Co., Ltd. (JP) | 2021-01-27 | — | — | EP | disclosed |
| US-20210000968-A1 | ALGINIC ACID DERIVATIVE BONDED TO NONSTEROIDAL ANTI-INFLAMMATORY COMPOUND | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2021-01-07 | — | — | US | disclosed |
| CN-112154158-A | Alginic acid derivatives with non-steroidal anti-inflammatory compounds attached | 持田制药株式会社 | 2020-12-29 | — | — | CN | disclosed |
| WO-2019189419-A1 | ANTI-CANCER AGENT-BONDED ALGINIC ACID DERIVATIVE | 持田製薬株式会社 | 2019-10-03 | — | — | WO | disclosed |
| WO-2003072098-A1 | USE OF SUBSTITUTED 3-PHENYL-5-ALKOXY-1,3,4-OXDIAZOLE-2-ONE FOR PRODUCING MEDICAMENTS THAT INHIBIT PANCREATIC LIPASE | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-09-04 | — | — | WO | disclosed |
| US-6596742-B1 | Inhibitory effect on the hormone-sensitive lipase, HSL. insecticides, controlling metabolism and multistage synthesis | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-07-22 | — | — | US | disclosed |
| EP-1214302-A1 | SUBSTITUTED 3-PHENYL-5-ALKOXI-1,3,4-OXDIAZOL-2-ONES AND THEIR USE AS LIPASE INHIBITORS | Aventis Pharma Deutschland GmbH (DE) | 2002-06-19 | — | — | EP | disclosed |
| EP-1169318-A1 | PRODRUGS OF THROMBIN INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 2002-01-09 | — | — | EP | disclosed |
| WO-2001017981-A1 | SUBSTITUTED 3-PHENYL-5-ALKOXI-1,3,4-OXDIAZOL-2-ONES AND THEIR USE AS LIPASE INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-03-15 | — | — | WO | disclosed |
| WO-2000061577-A1 | PRODRUGS OF THROMBIN INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 2000-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190943-A1 | ALGINIC ACID DERIVATIVE BONDED TO NONSTEROIDAL ANTI-INFLAMMATORY COMPOUND | ALG1, ALG8, ALG3 | APLNR 1559/4885 |
| US-20030236288-A1 | Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase | PNLIP, CEL, LIPE | APLNR 3025/4885 |
| US-20210000968-A1 | ALGINIC ACID DERIVATIVE BONDED TO NONSTEROIDAL ANTI-INFLAMMATORY COMPOUND | ALG1, ALG8, ALG3 | APLNR 1548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.